Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James L Pool

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Managed Care Pharmacy : JMCP|November 22, 2007
Direct renin inhibition: focus on aliskirenJames L Pool
American Journal of Hypertension|November 20, 2003
Is it time to move to multidrug combinations?James L Pool
Seminars in Nephrology|October 6, 2005
Clinical pharmacology of antihypertensive therapyAddison A Taylor, James L Pool
American Journal of Therapeutics|February 15, 2011
Clinical role of direct renin inhibition in hypertensionAddison A Taylor, James L Pool
Clinical Drug Investigation|November 6, 2009
The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trialJames L Pool, Robert Glazer, Nora Crikelair, et al.
Clinical Therapeutics|March 24, 2007
Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adultsJames L Pool, Robert Glazer, Myron Weinberger, et al.
American Journal of Hypertension|January 3, 2007
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartanJames L Pool, Roland E Schmieder, Michel Azizi, et al.
Clinical Science (London, England : 1979)|August 25, 2011
Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucoseTodd S Perlstein, Robert R Henry, Kieren J Mather, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Managed Care Pharmacy : JMCP|November 22, 2007
Direct renin inhibition: focus on aliskirenJames L Pool
American Journal of Hypertension|November 20, 2003
Is it time to move to multidrug combinations?James L Pool
Seminars in Nephrology|October 6, 2005
Clinical pharmacology of antihypertensive therapyAddison A Taylor, James L Pool
American Journal of Therapeutics|February 15, 2011
Clinical role of direct renin inhibition in hypertensionAddison A Taylor, James L Pool
Clinical Drug Investigation|November 6, 2009
The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trialJames L Pool, Robert Glazer, Nora Crikelair, et al.
Clinical Therapeutics|March 24, 2007
Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adultsJames L Pool, Robert Glazer, Myron Weinberger, et al.
American Journal of Hypertension|January 3, 2007
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartanJames L Pool, Roland E Schmieder, Michel Azizi, et al.
Clinical Science (London, England : 1979)|August 25, 2011
Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucoseTodd S Perlstein, Robert R Henry, Kieren J Mather, et al.
Pageof 1